Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab

Modern Rheumatology

Volumn 25, Issue 1, 2015, Pages 134-137

  Shima, Yoshihito ^a   Hosen, Naoki ^a   Hirano, Toru ^a   Arimitsu, Junsuke ^a   Nishida, Sumiyuki ^a   Hagihara, Keisuke ^a   Narazaki, Masashi ^a   Ogata, Atsushi ^a   Tanaka, Toshio ^a   Kishimoto, Tadamitsu ^b   Kumanogoh, Atsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Range of joint motion; Systemic sclerosis; Tocilizumab

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; BERAPROST; BOSENTAN; CEFDINIR; CYCLOSPORIN; DNA DIRECTED RNA POLYMERASE III; FUROSEMIDE; METHYLPREDNISOLONE; OMEPRAZOLE; PREDNISOLONE; TELMISARTAN; TEMOCAPRIL; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIALYSIS; DYSPNEA; ECHOCARDIOGRAPHY; ESOPHAGOSCOPY; FEMALE; GONIOMETRY; HEART CATHETERIZATION; HUMAN; HUMAN TISSUE; JOINT FUNCTION; METACARPOPHALANGEAL JOINT; MIDDLE AGED; PARENTERAL NUTRITION; PRIORITY JOURNAL; RANGE OF MOTION; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TRICUSPID VALVE REGURGITATION; DRUG EFFECTS; JOINT; JOINT CHARACTERISTICS AND FUNCTIONS; PATHOPHYSIOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; JOINTS; MIDDLE AGED; RANGE OF MOTION, ARTICULAR; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84983423248     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.874749     Document Type: Article

References (22)

1. Gurram M. Pahwa S. Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy. 1994:73:493-6.
2. Feghali CA. Bost KL. Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interbukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol. 1992:19:1207-11.
3. Hasegawa M. Sato S. Fujimoto M. Ihn H. Kikuchi K. Takehara K. Serum levels of interleukin 6 (IL-6). oncostatin M. soluble 1L-6 receptor, and soluble gpl30 in patients with systemic sclerosis. J Rheumatol. 1998:25:308-13.
4. Salo S. Hasegawa M, Takehara K. Serum lewis of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with syslemic sclerosis. J Dermatol Sci. 2001:27:140-6.
5. Khan K, Xu S, Nihtyanova S, Derrett-Smith E. Abraham D. Denton CP. Ong VH. Clinical and pathological significance of interleukin 6 overexpression in syslemic sclerosis. Ann Rheum Dis. 2012 |Epub ahead of print.
6. Kawaguchi Y. Hara M. Wright TM. Endogenous IL-1 alpha from syslemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999:103:1253-60.
7. Shima Y. Kuwahara Y. Murota H. Kitaba S. Kawai M. Hirano T. Arimitsu J. Narazaki M. Hagihara K. Ogata A. Katayama I, Kawase I, Kishimoto T. Tanaka T. The skin of patients with syslemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010:49: 2408-12.
8. Kuhn A. Haust M. Ruland V. Weber R. Verde P. Felder G. Ohmann C, Gensch K. Ruzicka T. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label. non-comparative trial. Rheumatology (Oxford). 2010:49:1336-45.
9. Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol. 2004:22:S87-9.
10. Steen VD. Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthr Rheum. 1998:41:1613-9.
11. Clements PJ. Furst DE. Wong WK. Maws M. White B. Wigley F. Weisman MH. Barr W et al. High-dose versus low-dose d-penicillamine in early diffuse syslemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthr Rheum. 1999:42:1194-203.
12. Kowal-Bielecka O. Landewe R. Avouac J. Chwiesko S. Miniati I. Czirjak L. Clements P. Denton C et al. EULAR recommendations for tic treatment of systemic sclerosis a report from the EULAR Scleroderma Trials and* Research group (EL'STAR). Ann Rheum Dis. 2009:68:620-8.
13. Pope JE. Bellamy N. Seibold JR. Baron M. Ellman M. Carette S. Smith CD. Chalmers IM. Hong P. O'Hanlon D. Kaminska E. Markland J. Sibley J. Catoggio L. Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthr Rheum. 2001:44:1351-8.
14. Tashkin DP. Elashoff R. Clements PJ. Goldin J. Roth MD. Furst DE. Arriola E. Silver R et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006:354: 2655-66.
15. Plotz PH. Klippel JH. Decker JL. Grauman D. Wolff B. Brown BC. Rutt G. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med! 1979:91:221-3.
16. Filaci G. Cutolo M. Scudeletti M. Castagneto C. Derchi L. Gianrossi R. Ropolo F. Zentilin P. Sulli A. Murdaca G. Ghio M. Indiveri F. Puppo F. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical resulLs and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999:38:992-6.
17. Denton CP. Sweny P. Abdulla A. Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994:33:90-2.
18. Stratton RJ. Wilson H. Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford). 2001:40:84-8.
19. Nihtyanova SI. Brough GM. Black CM. Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford). 2007:46:442-5.
20. Mendoza FA. Nagle SJ. Lee JB. Jimenez SA. A prospective observ ational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012:39:1241-7.
21. Denton CP. Engelhart M. Tvede N. Wilson H. Khan K. Shiwen X. Carreira PE. Diaz Gonzalez F. Black CM. Hoogen FH. An open- label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009:68:1433-9.
22. McGonagle D., Tan AL. Madden J. Rawstron AC. Rehman A. Emery P. Thomas S. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008:47:552-3.